The Lancet Haematology/LinkedIn
Oct 15, 2026, 19:18
Emerging Novel Therapies for Hereditary Hemorrhagic Telangiectasia – The Lancet Haematology
The Lancet Haematology shared a post on LinkedIn about a recent article by Hanny Al-Samkari, adding:
”A recent Review on emerging novel therapies for hereditary haemorrhagic telangiectasia (HHT) was presented at the 16th HHT International Scientific Conference in Cape Cod, Massachusetts.
Hanny Al-Samkari presented the Review, which examines the novel therapies now emerging for HHT and what they could mean for patients.”
Title: Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia
Author: Hanny Al-Samkari
Other posts about JTH on Hemostasis Today.
-
Oct 15, 2026, 19:41Looking Beyond Platelet Counts to Quality of Life in ITP – American Society of Hematology
-
Oct 15, 2026, 19:32Markus Gregorio Barbosa: Hepatic VPS35 and Cholesterol Homeostasis
-
Oct 15, 2026, 19:04Umberto Pensato: EVT Treatment Effects Across Perfusion Profiles in MeVO Stroke
-
Oct 15, 2026, 18:26Chanakya Nayudu: Presenting My Research at ISTH Congress 2026 in Paris
-
Oct 15, 2026, 18:09Maha Othman: Students Lead World Thrombosis Day 2026 Awareness Events
-
Oct 15, 2026, 17:52Jill de Mol։ Rapamycin Modulates Immune Responses in Aged Atherosclerosis
-
Oct 15, 2026, 17:41Victor Aboyans։ Think About Lipids in VTE
-
Oct 15, 2026, 17:08Babu Mia։ Targeting PPM1D to Eliminate Malignant Stem Cells in Myeloproliferative Neoplasms
-
Oct 15, 2026, 16:26Hauke Horstmann: Can an Existing Drug Be Repurposed to Treat Atherosclerosis?